PulseAugur
EN
LIVE 05:52:51

Orakl Oncology raises $34M for AI-driven virtual cancer patients

By PulseAugur Editorial · [1 sources] ·

Orakl Oncology, a Paris-based company, has secured $34 million in a Series A funding round. The company plans to use these funds to develop AI-powered virtual cancer patients. These models are intended to accelerate drug testing and efficacy prediction before clinical trials commence. AI

IMPACT This funding could accelerate drug discovery and development by enabling more efficient testing of potential treatments.

RANK_REASON Significant funding round for an AI-focused biotech company. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on Mastodon — mastodon.social →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Orakl Oncology raises $34M for AI-driven virtual cancer patients

How we ranked this

Signal score
13 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant funding round for an AI-focused biotech company. [lever_c_demoted from significant: ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Mastodon — mastodon.social TIER_1 English(EN) · [email protected] ·

    Paris-based Orakl Oncology has raised a 34M USD Series A to build AI-powered virtual cancer patients, models used to test drugs and predict their efficiency bef

    Paris-based Orakl Oncology has raised a 34M USD Series A to build AI-powered virtual cancer patients, models used to test drugs and predict their efficiency before they reach clinical trials. Swedish investor Norrsken and Paris-based VC Singular co-led the round. https:// sifted.…

    LINKS sifted.eu/…/exclusive-orakl-oncology-fund…

RELATED ENTITIES

RELATED TOPICS